Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)
Public ClinicalTrials.gov record NCT04142619. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I, Open-label Dose-escalation Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCARTCS1A (Allogenic Engineered T-cells Expressing Anti-CS1 Chimeric Antigen Receptor) Administered in Patients With Relapsed/Refractory Multiple Myeloma
Study identification
- NCT ID
- NCT04142619
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Cellectis S.A.
- Industry
- Enrollment
- 11 participants
Conditions and interventions
Conditions
Interventions
- UCARTCS1A Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 64 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 20, 2019
- Primary completion
- Jun 17, 2023
- Completion
- Jun 17, 2023
- Last update posted
- Sep 21, 2023
2019 – 2023
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCSF Medical Center- Helen Diller Family Comprehensive Cancer Center | San Francisco | California | 94115 | — |
| Sarah Cannon Research Institute - Colorado Blood Cancer Institute | Denver | Colorado | 80218 | — |
| Winship Cancer Institute Emory University | Atlanta | Georgia | 30322 | — |
| Mayo Clinical Cancer Center (MCCC) | Rochester | Minnesota | 55905 | — |
| Hackensack Meridian Health | Hackensack | New Jersey | 07601 | — |
| Sarah Cannon Research Institute - Tennessee Oncology | Nashville | Tennessee | 37203-1625 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Sarah Cannon Research Institute - Methodist Healthcare | San Antonio | Texas | 78229-6306 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04142619, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 21, 2023 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04142619 live on ClinicalTrials.gov.